Cargando…
Intranasal immunization with a flagellin-adjuvanted peptide anticancer vaccine prevents tumor development by enhancing specific cytotoxic T lymphocyte response in a mouse model
PURPOSE: Human papillomavirus (HPV) is a significant cause of cervical cancer-related deaths worldwide. Because HPV is a sexually transmitted mucosal pathogen, enhancement of antigen-specific mucosal immune response likely serves good strategy for vaccination. However, mucosal vaccines generally do...
Autores principales: | Nguyen, Chung Truong, Hong, Seol Hee, Ung, Thuan Trong, Verma, Vivek, Kim, Soo Young, Rhee, Joon Haeng, Lee, Shee Eun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Vaccine Society
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3710921/ https://www.ncbi.nlm.nih.gov/pubmed/23858404 http://dx.doi.org/10.7774/cevr.2013.2.2.128 |
Ejemplares similares
-
Optimal long peptide for flagellin-adjuvanted HPV E7 cancer vaccine to enhance tumor suppression in combination with anti-PD-1
por: Lee, Hye Hwa, et al.
Publicado: (2022) -
Flagellin is a strong vaginal adjuvant of a therapeutic vaccine for genital cancer
por: Lee, Shee Eun, et al.
Publicado: (2015) -
Deimmunization of flagellin for repeated administration as a vaccine adjuvant
por: Khim, Koemchhoy, et al.
Publicado: (2021) -
Tetanus toxin fragment C fused to flagellin makes a potent mucosal vaccine
por: Lee, Shee Eun, et al.
Publicado: (2015) -
Deglycosylation of eukaryotic-expressed flagellin restores adjuvanticity
por: Khim, Koemchhoy, et al.
Publicado: (2023)